Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates.
Fine needle aspirates from 82 patients with breast carcinoma were fixed in methacarn, double embedded in agar or gelatin, and then in paraffin wax. Sequential sections were stained with monoclonal antibodies to the oestrogen receptor-related protein P29 (antibody D5), carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA) and cytokeratin (CAM 5.2). Sixty-one of 82 (74%) aspirates provided sections suitable for immunostaining. Twenty-six (43%) were D5 positive, 23 (38%) CEA positive, 59 (97%) EMA positive, and 54 (89%) CAM 5.2 positive. Twenty-six of these patients were treated with some form of endocrine therapy. Twelve (46%) showed positive staining for D5. Eleven (92%) of the 12 D5-positive patients responded or had static disease, and 8% progressed. Of the 14 D5-negative tumours 43% responded or remained static, and 57% progressed. The difference in response between the D5-positive and the D5-negative tumours was significant (P less than 0.05, Fisher's exact test). There was no correlation between staining for CEA, EMA or cytokeratin and response to endocrine therapy.
Heyderman
E
E
Department of Histopathology, UMDS, St Thomas Hospital, London, UK.
Ebbs
S R
SR
Larkin
S E
SE
Brown
B M
BM
Haines
A M
AM
Bates
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle / Q000379:methods; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D011237:Predictive Value of Tests; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen